SMALL MOLECULE THERAPEUTICS

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer 2677
Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonne C. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Robert L. Coleman, and Anil K. Sood

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors 2700
Steven R. Whittaker, Glenn S. Cowley, Steve Wagner, Flora Luo, David E. Root, and Levi A. Garraway

Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma 2712
Matthias Ilmer, Agnès Garnier, Jody Vykoukal, Eckhard Alt, Dietrich von Schweinitz, Roland Kappler, and Michael Berger

Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling 2722
Dhanya K. Nambiar, Paulraj Rajamani, Gagan Deep, Anil K. Jain, Rajesh Agarwal, and Rana P. Singh

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System 2735

LARGE MOLECULE THERAPEUTICS

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study 2782
Sylvain Manfredi, Olivier Bouché, Philippe Roguier, Laetitia Dahah, Marie Anne Loriot, Thomas Aparicio, Pierre Luc Etienne, Jean Pierre Lafargue, Cédric Lécaillie, Jean Louis Legoux, Karine Le Malicot, Emilie Maillard, Thierry Leconte, Faiza Khémissa, Gilles Breyacher, Pierre Michel, Emmanuel Mity, and Laurent Bedenne

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors 2789
Ronit Mazor, Jingli Zhang, Laiman Xiang, Selamawit Addissie, Prince Awuah, Richard Beers, Rafit Hassan, and Ira Pastan
Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts
Xiaohua Ni, Yonggang Zhang, Kenji Zennami, Mark Castanares, Amarnath Mukherjee, Raju R. Raval, Haoming Zhou, Theodore L. DeWeese, and Shawn E. Lupold

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Wei Jiang, Na Liu, Xiao-Zhong Chen, Ying Sun, Bin Li, Xian-Yue Ren, Wei-Feng Qin, Ning Jiang, Ya-Fei Xu, Ying-Qin Li, Jian Ren, William CS Cho, Jing-Ping Yan, Jing Zeng, Li-Zhi Liu, Li Li, Ying Guo, Hai-Qiang Mai, Mu-Sheng Zeng, Tie-Bang Kang, Wei-Hua Jia, Jian-Yong Shao, and Jun Ma

Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients
Tongmeng Yan, Linlin Lu, Cong Xie, Jianmei Chen, Xiaojuan Peng, Lijun Zhu, Ying Wang, Qiang Li, Jian Shi, Fuyuan Zhou, Ming Hu, and Zhongqiu Liu

Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing

Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
ABOUT THE COVER

The cover image shows the structural model of LMB-T20, a highly potent recombinant immunotoxin consisting of an antimesothelin Fv fused to a portion of Pseudomonas exotoxin A. The toxin has a deletion of domain II and six point mutations in domain III that delete or greatly suppress the eight T-cell epitopes. For details, see the article by Mazor and colleagues on page 2789.